Adam R. Craig - 01 Jun 2022 Form 4/A - Amendment Insider Report for CTI BIOPHARMA CORP

Role
President and CEO, Director
Signature
Adam R. Craig
Issuer symbol
N/A
Transactions as of
01 Jun 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
03 Jun 2022, 19:15:06 UTC
Date Of Original Report
03 Jun 2022
Previous filing
11 Mar 2022
Next filing
06 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -27,000 -2.1% $0.000000 1,273,000 01 Jun 2022 Common Stock 27,000 $0.8411 Direct F1, F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -27,000 -2.1% $0.000000 1,246,000 02 Jun 2022 Common Stock 27,000 $0.8411 Direct F1, F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -18,223 -1.5% $0.000000 1,227,777 03 Jun 2022 Common Stock 18,223 $0.8411 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4/A amends the description of Title of Derivative Security previously reported on Form 4 filed on 6-3-2022.
F2 One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.